Murine monoclonal anti-TNF antibody administration has a beneficial effect on inflammatory bowel disease that develops in IL-10 knockout mice

Digestive Diseases and Sciences

Volumn 47, Issue 8, 2002, Pages 1723-1727

  Gratz, Raia ^a   Becker, Stuart ^a   Sokolowski, Nadia ^a   Schumann, Marcus ^a   Bass, David ^a   Malnick, Stephen D H ^a  

^a KAPLAN MEDICAL CENTER   (Israel)

Author keywords

Inflammatory bowel disease; Interleukin 10; Knockout mice; Tumor necrosis factor

Indexed keywords

INTERLEUKIN 10; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DISEASE MODEL; DRUG EFFECT; ENTERITIS; HISTOLOGY; INFLAMMATION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RECTUM HEMORRHAGE; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; INFLAMMATORY BOWEL DISEASES; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-10; MICE; MICE, KNOCKOUT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036335230     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016476024293     Document Type: Article

References (23)

1. Epidermiology of inflammatory bowel disease
2. Biologic therapy for inflammatory bowel disease
3. Tumour necrosis factor (TNF) binding proteins (soluble TNF receptor forms) with possible roles in inflammation and malignancy
4. Enhanced mucosal cytokine production in inflammatory bowel disease
5. Increased production of interleukin-1, interleukin-2 and soluble interleukin- 2 receptor in endoscopic mucosal biopsy specimens with inflammatory bowel disease
6. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation
7. Serum concentrations of tumour necrosis factor in childhood chronic inflammatory bowel disease
8. Infliximab approved for use in Crohn's disease: A report on the FDA GI Advisory Committee Conference
9. A short-term study of chimeric monoclonal antibody CA2 to tumor necrosis factor for Crohn's disease
10. Endoscopic and histological healing with Infliximab anti-tumor necrosis factor antibodies in Crohn's disease. A European Multicenter Trial
11. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (Infliximab) to maintain remission in Crohn's disease
12. Anti-inflammatory cytokines
13. Interleukin-10 deficient mice develop chronic enterocolitis
14. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis
15. Specific mangement of Crohn's disease
16. + Th1-like responses
17. Experimental models of IBD
18. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice
19. Helicobacter hepaticus triggers colitis in specific pathogen-free interleukin-10 (IL-10) -deficient mice through an IL-12 and gamma interferon-dependent mechanism
20. Antibiotic therapy attenuates colitis in interleukin-10 gene-deficient mice
21. The relationship between infliximab treatment and lymphoma in Crohn's disease
22. Antibodies to tumour necrosis factor α as treatment for Crohn's disease
23. Does administration of infliximab increase susceptibility to listeriosis?